S6196

Simvastatin

≥97% (HPLC), solid

• Sinónimos: MK-733, SVA
• Fórmula empírica (notación de Hill): C₂₅H₃₈O₅
• Número de CAS: 79902-63-9
• Peso molecular: 418.57
• Número MDL: MFCD00072007
• Código UNSPSC: 12352200
• ID de la sustancia en PubChem: 24724617
• NACRES: NA.77

Propiedades

• Ensayo: ≥97% (HPLC)
• Formulario: solid
• color: white
• mp: 127-132 °C (lit.)
• solubilidad: DMSO: ≥20 mg/mL
• emisor: Merck & Co., Inc., Kenilworth, NJ, U.S.
• temp. de almacenamiento: 2-8°C
• cadena SMILES: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC
• InChI: 1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
• Clave InChI: RYMZZMVNJRMUDD-HGQWONQESA-N
• Información sobre el gen: human ... HMGCR(3156) ; rat ... Hmgcr(25675)

Descripción

Descripción general

Simvastatin is a prodrug. Simvastatin is a semisynthetic derivative/analog of lovastatin. Simvastatin is insoluble in water but is soluble in polar organic solvents.[1]

Aplicación

Simvastatin has been used:

• as an inhibitor of HMG CoA reductase (HMGCR)[2]
• to study its effects on epithelial to mesenchymal transition (EMT) and the prognosis of patients with lung adenocarcinoma[3]
• in in vivo studies to test its effect on brain tumor−initiating cells (BTIC) viability and cell proliferation[4]
• to study the role of adenosine triphosphate (ATP)-binding cassette transporter A7 in phagocytosis of Jurkat cells
• to study the effect on endothelial dysfunction and inflammation in mice

Acciones bioquímicas o fisiológicas

Simvastatin is a specific inhibitor of HMG-CoA reductase and cholesterol lowering drug.

Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia, as it reduces levels of low-density lipoproteins and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid, and can be activated prior to use with NaOH in EtOH treatment. It is a synthetic analog of lovastatin (Cat. No. M2147).

Simvastatin is a specific inhibitor of HMG-CoA reductase,[2] the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. It is used in the treatment of hypercholesterolemia,[1] as it reduces levels of low-density lipoproteins cholesterol and triglycerides, and raises high-density lipoprotein levels. Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid and can be activated prior to use with NaOH in EtOH treatment. It may also have beneficial effects on endothelial function, inflammation, smooth muscle cell function, vascular wall function,[5] hemostasis and LDL oxidation.

Características y beneficios

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Pictogramas: GHS08
• Palabra de señalización: Warning
• Frases de peligro: H361d
• Consejos de prudencia: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Clasificaciones de peligro: Repr. 2
• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable
• Equipo de protección personal: Eyeshields, Gloves, type N95 (US)